R. Jonathan Henderson, MD, discusses incorporating immunotherapy agents into practice in patients with bladder cancer.
R. Jonathan Henderson, MD
Advertisement
Articles by R. Jonathan Henderson, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma
2
Zipalertinib Plus Chemotherapy Improves PFS in First-Line EGFR Exon 20 Insertion+ NSCLC
3
Dr Banerjee on the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
4
Pooled Analysis Reveals Strong Pirtobrutinib Efficacy in Frontline CLL
5